Panel Community Conversations track
AASLD/CHESS: Advances in the Screening, Diagnosis and Treatment of Liver Fibrosis
Sat, Nov 7, 2026 · 3:45–4:45 PM MST Convention Center: Mile High Ballroom 2A-3A, Colorado Convention Center
About this session
Liver fibrosis is a key determinant of liver-related morbidity and mortality across a broad spectrum of chronic liver diseases, including MASLD/MASH, viral hepatitis, and alcohol-related liver disease. Recent years have witnessed remarkable progress in non-invasive assessment tools, including serum biomarkers, imaging technologies, artificial intelligence–assisted risk stratification, and multi-omics approaches, which are transforming the screening, diagnosis and monitoring of liver fibrosis.